These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1684194)

  • 1. Bowel microorganisms--a target for selective antimicrobial control.
    van Saene HK; Percival A
    J Hosp Infect; 1991 Sep; 19 Suppl C():19-41. PubMed ID: 1684194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protecting neutropenic patients from bowel-derived organisms.
    Warren RE
    J Hosp Infect; 1991 Sep; 19 Suppl C():43-58. PubMed ID: 1684195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why not performing susceptibility test for trimethoprim-sulphamethoxazole?
    Hagiya H
    J Chemother; 2015 Feb; 27(2):124-5. PubMed ID: 25248022
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.
    Daneman N; Sarwar S; Fowler RA; Cuthbertson BH;
    Lancet Infect Dis; 2013 Apr; 13(4):328-41. PubMed ID: 23352693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolones in the treatment of Salmonella carriers.
    Rodríguez-Noriega E; Andrade-Villanueva J; Amaya-Tapia G
    Rev Infect Dis; 1989; 11 Suppl 5():S1179-87. PubMed ID: 2672248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever.
    Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Bjökholm M
    Scand J Infect Dis; 1996; 28(3):297-303. PubMed ID: 8863366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin.
    Epstein ME; Amodio-Groton M; Sadick NS
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):365-81; quiz 382-4. PubMed ID: 9308549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis.
    Fox BC; Sollinger HW; Belzer FO; Maki DG
    Am J Med; 1990 Sep; 89(3):255-74. PubMed ID: 2118307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective decontamination of the digestive tract (SDD) in intensive care patients: a critical evaluation of the clinical, bacteriological and epidemiological benefits.
    van Saene HK; Stoutenbeek CP; Hart CA
    J Hosp Infect; 1991 Aug; 18(4):261-77. PubMed ID: 1682365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature.
    Wolff MA; Young CL; Ramphal R
    Clin Infect Dis; 1993 Jun; 16(6):772-7. PubMed ID: 8329509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprophylaxis of gram-negative infections in neutropenic patients.
    Klastersky J
    Eur Urol; 1990; 17 Suppl 1():40-5. PubMed ID: 2162299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings.
    Forna F; McConnell M; Kitabire FN; Homsy J; Brooks JT; Mermin J; Weidle PJ
    AIDS Rev; 2006; 8(1):24-36. PubMed ID: 16736949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection.
    DiRienzo AG; van Der Horst C; Finkelstein DM; Frame P; Bozzette SA; Tashima KT
    AIDS Res Hum Retroviruses; 2002 Jan; 18(2):89-94. PubMed ID: 11839141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares.
    Brown MP; Gronwall R; Castro L
    Am J Vet Res; 1988 Jun; 49(6):918-22. PubMed ID: 3261143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral fluoroquinolones prevent translocation of enterobacteria following combined liver-small bowel transplantation in pigs.
    Privitera G; Rossi G; Conte E; Gatti S; Matinato C; Reggiani P
    Transplant Proc; 1996 Oct; 28(5):2669-70. PubMed ID: 8908003
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of sulfamethoxazole and trimethoprim in swimming crabs (Portunus trituberculatus) and in vitro antibacterial activity against Vibrio: PK/PD of SMZ-TMP in crabs and antibacterial activity against Vibrio.
    Fu G; Peng J; Wang Y; Zhao S; Fang W; Hu K; Shen J; Yao J
    Environ Toxicol Pharmacol; 2016 Sep; 46():45-54. PubMed ID: 27434870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
    Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
    Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia.
    Foster MT
    Pharmacotherapy; 1993; 13(2 Pt 2):45S-50S. PubMed ID: 8474938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens.
    Romani AA; Baroni MC; Taddei S; Ghidini F; Sansoni P; Cavirani S; Cabassi CS
    J Pept Sci; 2013 Sep; 19(9):554-65. PubMed ID: 23893489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.